Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma

Atherosclerosis

Volumn 141, Issue SUPPL. 1, 1998, Pages

  Mamo, John C L ^a   Proctor, Spencer D ^a   Smith, Darrin ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chylomicron remnants; Clearance mechanism; Lesions

Indexed keywords

CHOLESTEROL; CHYLOMICRON; LIPOPROTEIN; STEROL; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIET; DYSLIPIDEMIA; INFLAMMATION; INTIMA; PRIORITY JOURNAL; SUBENDOTHELIUM; THROMBOSIS;

EID: 0031743318     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00220-2     Document Type: Conference Paper

References (48)

1. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. Arch Int Med 1959;103:4-8.
2. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
3. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
4. Hennessy LK, Osada J, Ordovas JM, Nicolosi RJ, Stucchi AF, Brousseau ME, et al. Effects of dietary fats and cholesterol on liver lipid content and hepatic apolipoprotein A-I, B, and E and LDL receptor mRNA levels in cebus monkeys. J Lipid Res 1992;33:351-60.
5. Lairon D. Nutritional and metabolic aspects of postprandial lipaemia. Reprod Nutr Dev 1996;36:345-55.
6. Proctor SD, Mamo JCL. Arterial fatty lesions have increased uptake of chylomicron-remnants but not low density lipoprotein. Coron Artery Dis 1996;7:239-45.
7. Simionescu N, Simionescu M. Cellular interactions of lipoproteins with the vascular endothelium: endocytosis and transcytosis. Targital. Diagn Ther 1991;5:45-95.
8. Mamo JCL. Atherosclerosis as a postprandial disease. Endocrinol Metab 1995;2:229-44.
9. Thompson GR. A handbook of hyperlipidaemia. London: Current Science, 1990.
10. Nicoll A, Duffield R, Lewis B. Flux of plasma lipoproteins into human arterial intima. Atherosclerosis 1981;39:229-42.
11. Pittman RC, Carew TE, Glass CK, Green SR, Taylor CA Jr., Attie AD. A radioiodinated, intracellular trapped ligand for determining the sites of plasma protein degradation in vivo. Biochem J 1983;212:791-800.
12. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol fed rabbits. J Lipid Res 1988;29:1491-500.
13. Stender S, Hjelms E. In vivo transfer of cholesterol ester from high and low density plasma lipoproteins into human aortic tissue. Arterioscler Thromb 1988;8:252-62.
14. Proctor SD and Mamo JCL. Retention of fluorescent labelled chylomicron-remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from postprandial lipoproteins. Eur J Clin Invest 1988;28:497-503.
15. Chait A, Chang MV, Olin K, Wight T. Interaction of oxidised LDL with arterial proteoglycan. Atherosclerosis 1997;134:197.
16. McGee DL, Reed DM, Yano K, Kagan A, Tillotson J. Ten year incidence of coronary heart disease in the Honolulu Heart Program. Am J Epidemiol 1984;119:733-41.
17. Keys A. Dietary lipids and ischaemic heart disease - progress in 20 years. Am J Clin Nutr 1988;47:965-9.
18. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, McNamara JR, Ordovas JM. Lipoproteins, nutrition, aging, and atherosclerosis. Am J Clin Nutr 1995;61:726S-740.
19. Redgrave TG. Formation and metabolism of chylomicrons. Int Rev Physiol 1983;28:103-30.
20. Martins IJ, Sainsbury AJ, Mamo JC, Redgrave TG. Lipid and apolipoprotein B-48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron-like emulsions in insulin-deficient rats. Diabetologia 1994;37:238-46.
21. Huff MW, Burnett JR. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Curr Opin Lipid 1997;8:138-45.
22. Watts GF, Burke V. Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: new evidence, implications and outstanding issues. Curr Opin Lipidol 1996;7:341-55.
23. Havel RJ. Chylomicron remnants: hepatic receptors and metabolism. Curr Opin Lipidol 1995;6:312-6.
24. Kita T, Goldstein JL, Brown MS, Watanabe Y, Hornick CA, Havel RJ. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci USA 1982;79:3623-7.
25. Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in 'knockout' mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 1994;91:4431-5.
26. Rubinsztein DC, Cohen JC, Berger M, van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990;86:1306-12.
27. Mamo JCL, Smith D, Yu KC, Kawaguchi A, Harada-Shiba M, Yamamura T. et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolemia. Eur J Clin Invest 1988;28:379-84.
28. Bowler A, Redgrave TG, Mamo JCL. Chylomicron remnant clearance in homozygote and heterozygote Watanabe heritable hyperlipidemic rabbits is defective. Lack of evidence for an independent chylomicron-remnant receptor. Biochem J 1991;276:381-6.
29. Assadollahi F, Cavallero E, Buxtorf JC, Jacotot B, Beaumont JL. Familial xanthomatous hypercholesterolemia - abnormal exogenous lipid metabolism evidenced by the vitamin A test. Ann Nutr Metab 1994;38:307-12.
30. Hussain MM, Innerarity TL, Brecht WJ, Mahley RW. Chylomicron metabolism in normal, cholesterol-fed and Watanabe heritable hyperlipidemic rabbits - saturation of the sequestration step of the remnant pathway. J Biol Chem 1995;270:8578-87.
31. Mortimer BC, Beveridge DJ, Martin IJ, Redgrave TG. Intracellular localisation and metabolism of chylomicron remnants in the livers of LDL-receptor deficient mice and apo E deficient mice. Evidence for slow metabolism via an alternative pathway. J Biol Chem 1995;270:28767-76.
32. Ishibashi S, Perry S, Chen Z, Osuga J, Shimada M, Ohashi K, et al. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron-remnants - a quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem 1996;271:22422-7.
33. Choi SY, Cooper AD. A comparison of the roles of the low density lipoprotein (LDL) receptor and the LDL receptor related protein/alpha 2-macroglobulin receptor in chylomicron remnant removal in the mouse in vivo. J Biol Chem 1993;268:15804-11.
34. Biesiegel U, Krapp A, Weber W, Olivecrona G. The role of alpha 2m/LRP in chylomicron remnant metabolism. Ann N Y Acad Sci 1994;10:737-69.
35. Mamo JCL, Yu KCW, Elsegood CL, Smith D, Vine DF, Gennat HC, et al. Is atherosclerosis exclusively a post-prandial phenomenon? Clin Exp Pharmacol Physiol 1997;24:288-93.
36. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of postprandial triglyceride rich lipoproteins in healthy men by retinyl ester labelling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 1995;15:199-207.
37. Cohn JS. Postprandial lipid metabolism. Curr Opini Lipidol 1994;5:185-90.
38. Martins IJ, Hopkins L, Joll CA, Redgrave TG. Interactions between model triacylglycerol rich lipoproteins and high density lipoproteins in rat, rabbit and man. Biochim Biophys Acta 1991;1081:328-38.
39. Peel AS, Zampelas A, Williams CM, Gould BJ. A novel anti-serum specific to apolipoprotein B-48: application in the investigation of postprandial lipidemia in humans. Clin Sci 1993;85:521-4.
40. Isherwood SG, Williams CM, Griffin BA, Gould BJ. Chylomicron remnants are present in the low density lipoprotein fraction (Sf0-12) as detected by a specific antibody to apolipoprotein B-48. Atherosclerosis 1995;115:7.
41. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993;223:53-71.
42. Smith D, Proctor SD, Mamo JCL. A highly sensitive assay for quantitation of apolipoprotein B-48 using an antibody to human apolipoprotein B and enhance chemiluminescence. Ann Clin Biochem 1997;34:185-9.
43. Slyper A. A fresh look at the atherogenic remnant hypothesis. Lancet 1993;340:289-91.
44. Smith D, Watts GF, Mamo JCL. Postprandial chylomicron response may be predicted by a single measurment of plasma apolipoprotein B48 in the fasting state. Fur J Clin Invest 1998 (in press).
45. Steiner G. Triglyceride-rich lipoproteins and atherosclerosis, from fast to feast. Ann Med 1993;25:431-5.
46. Groot PH, van Stiphout WA, Krauss XH, Jansen H, van Tol A, van Ramshorst E, et al. Postprandial lipoprotein metabolism in normolipidaemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653-62.
47. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, et al. Clearance of chylomicron remnants in normolipidemic patients with coronary artery disease - case control study over three years. Br Med J 1996;312:935-9.
48. Mamo JCL, Wheeler JR. Chylomicrons or their remnants penetrate rabbit thoracic aorta as efficiently as smaller macro-molecules including low density lipoprotein, high density lipoprotein and albumin. Coron Artery Dis 1994;5:695-705.